Michael C. Quirk - Apr 10, 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Chief Scientific Officer and Interim Head of R&D
Signature: Brandon Marsh, attorney in fact for Michael C. Quirk
Stock symbol: SAGE
Transactions as of: Apr 10, 2025
Transactions value $: -$5,086
Form type: 4
Date filed: 4/11/2025, 04:09 PM
Previous filing: Apr 2, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Award	$0	+933	+3.21%	$0.00	30K	Apr 10, 2025	Direct	F1
transaction	SAGE	Common Stock	Tax liability	-$2.16K	-312	-1.04%	$6.91	29.7K	Apr 10, 2025	Direct
transaction	SAGE	Common Stock	Award	$0	+1.27K	+4.27%	$0.00	31K	Apr 10, 2025	Direct	F2
transaction	SAGE	Common Stock	Tax liability	-$2.93K	-424	-1.37%	$6.91	30.6K	Apr 10, 2025	Direct

Showing 1 to 4 of 4 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 11, 2022, the reporting person was granted Performance Restricted Stock Units (PSUs) to acquire a total of 2,666 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on April 10, 2025, resulting in the vesting of the PSUs as to 933 shares.
F2	On October 3, 2022, the reporting person was granted PSUs to acquire a total of 3,625 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on April 10, 2025, resulting in the vesting of the PSUs as to 1,269 shares.

Remarks:

Chief Scientific Officer and Interim Head of R&D